1707 ET - Drugmaker Eli Lilly suffered its largest one-day loss of market capitalization on record-more than $99 billion-after rival Novo Nordisk struck a deal with CVS that threatens Lilly's growing dominance in the booming anti-obesity drug market. Lilly shares closed down 11.7% at $794.10, their largest one-day percentage decrease since 2008, according to Dow Jones Market Data. CVS's pharmacy-benefits manager will favor coverage of Novo's Wegovy, which means Lilly's competing weight-loss drug Zepbound will be a more costly option for CVS plan members. The Novo-CVS deal is "bad news" for Lilly and will hurt Zepbound's momentum when the new coverage takes effect in July, Leerink Partners analyst David Risinger wrote in a research note. (peter.loftus@wsj.com)
(END) Dow Jones Newswires
May 01, 2025 17:07 ET (21:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.